Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung
cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed
to merge the selectivity of monoclonal antibodies with cell killing properties of …

Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors
and correlates with poor prognosis. We developed the novel TROP2-directed antibody–drug …

PURPOSE Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting
of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) …

Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in
modern drug development. By harnessing the powers of both cytotoxic chemotherapy and …

Members of the human epidermal growth factor receptor (HER) family, which includes HER1
(also known as EGFR), HER2, HER3 and HER4, have played a central role in regulating cell …

Trop2 is a transmembrane glycoprotein and calcium signal transducer with limited
expression in normal human tissues. It is consistently overexpressed in a variety of …